Share
.webp)
.webp)
.webp)
.webp)
Audrey Duval Derveloy
Sanofi has announced the appointment of Audrey Duval Derveloy as Executive Vice President, Global Head of Corporate Affairs.
In this role, she will become a member of Sanofi’s Executive Committee, reporting directly to CEO Paul Hudson, and will be based in Paris.
Audrey will oversee Sanofi’s global stakeholder engagement and lead the company’s corporate social responsibility strategy, including the not-for-profit Global Health Unit and Sanofi’s philanthropic arm, Foundation S. She will also continue in her position as President of Sanofi France, where she will support and coordinate the company’s representation to various external stakeholders in the country.
“I am very pleased to welcome Audrey to our Executive Committee,” said Paul Hudson, Chief Executive Officer of Sanofi. “Her leadership over the past two years has been instrumental in modernizing our operations in France. She has effectively supported our strategic priorities and showcased Sanofi as a leading healthcare company in our home market. This experience, combined with her business acumen and ability to inspire teams, positions her to drive our global external engagement strategy and play a crucial role in our ambitions to transform medicine for patients worldwide.”
Audrey joined Sanofi from Novartis as President of Sanofi France in September 2022. A physician by training, she began her career in public hospitals in Paris before serving as a researcher at the Pasteur Research Center of Hong Kong University. She later worked as a Scientific Expert at Salusmed in Hong Kong and returned to France to join Pfizer, focusing on medical affairs in endocrinology, transplant, and rheumatology. Audrey advanced her career at Novartis in France, ultimately becoming Business Franchise Head for Ophthalmology and, in 2020, Country President for Novartis operations in Ireland. She holds a Medical Doctorate from the Paris Faculté de Médecine Cochin and a Bachelor of Science in Medical Biology.
“I have witnessed firsthand the unwavering commitment of our employees in France to serving patients around the world,” said Audrey Duval Derveloy, Executive Vice President, Global Head of Corporate Affairs at Sanofi. “Behind each of our successes—from the launch of Beyfortus against RSV to our environmental initiatives and the mobilization of thousands of employees for our partnership with Paris 2024—our Corporate Affairs teams have been integral. It is with this strength in mind that I take on these new responsibilities as we continue to modernize Sanofi and pursue our ambition to become an immunology powerhouse.”
